|
1
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Bergami P: The role of mitogen- and
stress-activated protein kinase pathways in melanoma. Pigment Cell
Melanoma Res. 24:902–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sullivan RJ and Flaherty K: MAP kinase
signaling and inhibition in melanoma. Oncogene. 32:2373–2379. 2013.
View Article : Google Scholar
|
|
4
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al; BRIM-3 Study Group. Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al; METRIC Study Group. Improved survival with MEK inhibition in
BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar
|
|
9
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sullivan RJ and Flaherty KT: Resistance to
BRAF-targeted therapy in melanoma. Eur J Cancer. 49:1297–1304.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fedorenko IV, Gibney GT, Sondak VK and
Smalley KSM: Beyond BRAF: Where next for melanoma therapy? Br J
Cancer. 112:217–226. 2015. View Article : Google Scholar :
|
|
13
|
Spagnolo F, Ghiorzo P, Orgiano L,
Pastorino L, Picasso V, Tornari E, Ottaviano V and Queirolo P:
BRAF-mutant melanoma: Treatment approaches, resistance mechanisms,
and diagnostic strategies. Onco Targets Ther. 8:157–168. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yadav V, Zhang X, Liu J, Estrem S, Li S,
Gong XQ, Buchanan S, Henry JR, Starling JJ and Peng SB:
Reactivation of mitogen-activated protein kinase (MAPK) pathway by
FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in
human B-RAF V600E mutant melanoma. J Biol Chem. 287:28087–28098.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sabbatino F, Wang Y, Wang X, Flaherty KT,
Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, et
al: PDGFRα up-regulation mediated by sonic hedgehog pathway
activation leads to BRAF inhibitor resistance in melanoma cells
with BRAF mutation. Oncotarget. 5:1926–1941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Huang SK, Marzese DM, Hsu SC,
Kawas NP, Chong KK, Long GV, Menzies AM, Scolyer RA, Izraely S, et
al: Epigenetic changes of EGFR have an important role in BRAF
inhibitor-resistant cutaneous melanomas. J Invest Dermatol.
135:532–541. 2015. View Article : Google Scholar
|
|
17
|
Halaban R, Zhang W, Bacchiocchi A, Cheng
E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y and
Sznol M: PLX4032, a selective BRAFV600E kinase
inhibitor, activates the ERK pathway and enhances cell migration
and proliferation of BRAF melanoma cells. Pigment Cell Melanoma
Res. 23:190–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Girotti MR, Pedersen M, Sanchez-Laorden B,
Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes
A, Gore M, et al: Inhibiting EGF receptor or SRC family kinase
signaling overcomes BRAF inhibitor resistance in melanoma. Cancer
Discov. 3:158–167. 2013. View Article : Google Scholar
|
|
19
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of
a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci USA. 105:3041–3046. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vultur A, Villanueva J, Krepler C, Rajan
G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, et al: MEK
inhibition affects STAT3 signaling and invasion in human melanoma
cell lines. Oncogene. 33:1850–1861. 2014. View Article : Google Scholar
|
|
21
|
Zubrilov I, Sagi-Assif O, Izraely S,
Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C,
Couraud PO, Hoon DSB, et al: Vemurafenib resistance selects for
highly malignant brain and lung-metastasizing melanoma cells.
Cancer Lett. 361:86–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanchez-Laorden B, Viros A, Girotti MR,
Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S,
Hayes A, Gore M, et al: BRAF inhibitors induce metastasis in RAS
mutant or inhibitor-resistant melanoma cells by reactivating MEK
and ERK signaling. Sci Signal. 7:ra302014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vergani E, Vallacchi V, Frigerio S, Deho
P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA,
Rivoltini L, et al: Identification of MET and SRC activation in
melanoma cell lines showing primary resistance to PLX4032.
Neoplasia. 13:1132–1142. 2011. View Article : Google Scholar
|
|
24
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M, et al: The Genome Analysis Toolkit: A MapReduce framework for
analyzing next-generation DNA sequencing data. Genome Res.
20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang H and Wang K: Genomic variant
annotation and prioritization with ANNOVAR and wANNOVAR. Nat
Protoc. 10:1556–1566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pepponi R, Marra G, Fuggetta MP,
Falcinelli S, Pagani E, Bonmassar E, Jiricny J and D’Atri S: The
effect of O6-alkylguanine-DNA alkyltransferase and
mismatch repair activities on the sensitivity of human melanoma
cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and
cisplatin. J Pharmacol Exp Ther. 304:661–668. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Caporali S, Falcinelli S, Starace G, Russo
MT, Bonmassar E, Jiricny J and D’Atri S: DNA damage induced by
temozolomide signals to both ATM and ATR: Role of the mismatch
repair system. Mol Pharmacol. 66:478–491. 2004.PubMed/NCBI
|
|
29
|
Ruffini F, D’Atri S and Lacal PM:
Neuropilin-1 expression promotes invasiveness of melanoma cells
through vascular endothelial growth factor receptor-2-dependent and
-independent mechanisms. Int J Oncol. 43:297–306. 2013.PubMed/NCBI
|
|
30
|
Naber HP, Wiercinska E, Ten Dijke P and
van Laar T: Spheroid assay to measure TGF-β-induced invasion. J Vis
Exp. 57:e33372011.
|
|
31
|
Merz C, Strecker A, Sykora J, Hill O,
Fricke H, Angel P, Gieffers C and Peterziel H: Neutralization of
the CD95 ligand by APG101 inhibits invasion of glioma cells in
vitro. Anticancer Drugs. 26:716–727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lacal PM, Failla CM, Pagani E, Odorisio T,
Schietroma C, Falcinelli S, Zambruno G and D’Atri S: Human melanoma
cells secrete and respond to placenta growth factor and vascular
endothelial growth factor. J Invest Dermatol. 115:1000–1007. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Falchook GS, Long GV, Kurzrock R, Kim KB,
Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A,
et al: Dose selection, pharmacokinetics, and pharmacodynamics of
BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res.
20:4449–4458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smalley KS, Lioni M and Herlyn M: Life
isn’t flat: Taking cancer biology to the next dimension. In Vitro
Cell Dev Biol Anim. 42:242–247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lacal PM, Ruffini F, Pagani E and D’Atri
S: An autocrine loop directed by the vascular endothelial growth
factor promotes invasiveness of human melanoma cells. Int J Oncol.
27:1625–1632. 2005.PubMed/NCBI
|
|
36
|
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo
JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al: BRAF inhibition
increases tumor infiltration by T cells and enhances the antitumor
activity of adoptive immunotherapy in mice. Clin Cancer Res.
19:393–403. 2013. View Article : Google Scholar
|
|
37
|
Beazley-Long N, Gaston K, Harper SJ,
Orlando A and Bates DO: Novel mechanisms of resistance to
vemurafenib in melanoma - V600E B-Raf reversion and switching
VEGF-A splice isoform expression. Am J Cancer Res. 5:433–441.
2014.
|
|
38
|
Ferrara N, Hillan KJ, Gerber HP and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Keating GM: Bevacizumab: A review of its
use in advanced cancer. Drugs. 74:1891–1925. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koch S, Tugues S, Li X, Gualandi L and
Claesson-Welsh L: Signal transduction by vascular endothelial
growth factor receptors. Biochem J. 437:169–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Graells J, Vinyals A, Figueras A, Llorens
A, Moreno A, Marcoval J, Gonzalez FJ and Fabra A: Overproduction of
VEGF concomitantly expressed with its receptors promotes growth and
survival of melanoma cells through MAPK and PI3K signaling. J
Invest Dermatol. 123:1151–1161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Greger JG, Eastman SD, Zhang V, Bleam MR,
Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L and
Gilmer TM: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors
overcome acquired resistance to the BRAF inhibitor GSK2118436
dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther.
11:909–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar
|
|
46
|
Orgaz JL and Sanz-Moreno V: Emerging
molecular targets in melanoma invasion and metastasis. Pigment Cell
Melanoma Res. 26:39–57. 2013. View Article : Google Scholar
|
|
47
|
Ghosh S, Basu M and Roy SS: ETS-1 protein
regulates vascular endothelial growth factor-induced matrix
metalloproteinase-9 and matrix metalloproteinase-13 expression in
human ovarian carcinoma cell line SKOV-3. J Biol Chem.
287:15001–15015. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar
|
|
49
|
Carlino MS, Gowrishankar K, Saunders CAB,
Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long
GV, et al: Antiproliferative effects of continued mitogen-activated
protein kinase pathway inhibition following acquired resistance to
BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther.
12:1332–1342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chan MMK, Haydu LE, Menzies AM, Azer MWF,
Klein O, Lyle M, Clements A, Guminski A, Kefford RF and Long GV:
The nature and management of metastatic melanoma after progression
on BRAF inhibitors: Effects of extended BRAF inhibition. Cancer.
120:3142–3153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Das Thakur M, Salangsang F, Landman AS,
Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart
DD: Modelling vemurafenib resistance in melanoma reveals a strategy
to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hartsough EJ, Basile KJ and Aplin AE:
Beneficial effects of RAF inhibitor in mutant BRAF splice
variant-expressing melanoma. Mol Cancer Res. 12:795–802. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mehnert JM, McCarthy MM, Jilaveanu L,
Flaherty KT, Aziz S, Camp RL, Rimm DL and Kluger HM: Quantitative
expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma
tissue microarrays. Hum Pathol. 41:375–384. 2010. View Article : Google Scholar
|
|
54
|
Jiang CC, Lai F, Thorne RF, Yang F, Liu H,
Hersey P and Zhang XD: MEK-independent survival of B-RAFV600E
melanoma cells selected for resistance to apoptosis induced by the
RAF inhibitor PLX4720. Clin Cancer Res. 17:721–730. 2011.
View Article : Google Scholar
|
|
55
|
Shi H, Kong X, Ribas A and Lo RS:
Combinatorial treatments that overcome PDGFRβ-driven resistance of
melanoma cells to V600EB-RAF inhibition. Cancer Res. 71:5067–5074.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Atefi M, von Euw E, Attar N, Ng C, Chu C,
Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al:
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
co-targeting the AKT/mTOR pathway. PLoS One. 6:e289732011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Su F, Bradley WD, Wang Q, Yang H, Xu L,
Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, et al:
Resistance to selective BRAF inhibition can be mediated by modest
upstream pathway activation. Cancer Res. 72:969–978. 2012.
View Article : Google Scholar
|
|
58
|
Lassen A, Atefi M, Robert L, Wong DJ,
Cerniglia M, Comin-Anduix B and Ribas A: Effects of AKT inhibitor
therapy in response and resistance to BRAF inhibition in melanoma.
Mol Cancer. 13:832014. View Article : Google Scholar : PubMed/NCBI
|
